|
WO2016059548A1
|
|
Processes for the preparation of dabrafenib
|
|
WO2016038590A1
|
|
Process for the preparation of crystalline form i of regorafenib
|
|
WO2016038560A1
|
|
Process for the preparation of enzalutamide
|
|
WO2016038542A2
|
|
Solid forms of sofosbuvir
|
|
WO2016038532A1
|
|
Amorphous treprostinil diethanolamine
|
|
WO2016035042A1
|
|
Process for the preparation of canagliflozin
|
|
WO2016012934A1
|
|
Process for making lomitapide mesylate
|
|
WO2015193778A1
|
|
Crystalline form of levomefolate calcium
|
|
WO2015177758A1
|
|
Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base
|
|
WO2015162551A1
|
|
Process for the preparation of apixaban
|
|
WO2015145324A1
|
|
Process for the preparation of cobicistat
|
|
WO2015140765A1
|
|
A premix of crystalline raltegravir potassium salt and a process for the preparation thereof
|
|
WO2015125082A1
|
|
Improved process for the preparation of ritonavir
|
|
WO2015107451A2
|
|
Purification of tenofovir alafenamide and its intermediates
|
|
KR20160098495A
|
|
Process for the preparation of empagliflozin
|
|
WO2015092752A1
|
|
Novel crystalline form of dolutegravir sodium
|
|
WO2015092739A1
|
|
Process for preparation of alogliptin
|
|
WO2015087228A1
|
|
Process for the preparation of cabazitaxel and its solvates
|
|
WO2015083066A1
|
|
Preparation of cobicistat intermediates
|
|
WO2015079415A1
|
|
Amorphous cobicistat solid dispersion
|
